Home > Insider Trading > Filing (0001225208-13-017647)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1385187	Covidien Plc	COV	Surgical & Medical Instruments & Apparatus (3841)	980624794

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1400569	H John Masterson	C/O Covidien 15 Hampshire Street Mansfield MA 02048	Svp And General Counsel	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Ordinary Shares	Acquisiton	2013-08-08	30,383	$39.18	93,273	No	4	M	Direct
Ordinary Shares	Disposition	2013-08-08	30,383	$63.90	62,890	No	4	S	Direct
Ordinary Shares	Acquisiton	2013-08-09	36,500	$43.44	99,390	No	4	M	Direct
Ordinary Shares	Acquisiton	2013-08-09	10,733	$42.39	110,123	No	4	M	Direct
Ordinary Shares	Disposition	2013-08-09	47,233	$63.69	62,890	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Stock Option (Right to Buy)	Disposition	2013-08-08	30,383	$0.00	30,383	$39.18
Ordinary Shares	Stock Option (Right to Buy)	Disposition	2013-08-09	36,500	$0.00	36,500	$43.44
Ordinary Shares	Stock Option (Right to Buy)	Disposition	2013-08-09	10,733	$0.00	10,733	$42.39

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
30,384	2020-11-30	No	4	M	Direct
12,167	2019-11-30	No	4	M	Direct
32,202	2021-11-30	No	4	M	Direct

Footnotes

Includes unvested restricted stock units and associated unvested dividend equivalent units, the number of which were adjusted in connection with the recent spin-off of Covidien's pharmaceuticals business. Also includes 63 shares acquired in connection with the Issuer's employee stock purchase plan since the date of the Reporting Person's most recently filed Form 4.
The price reported is the weighted average price. Shares were sold in multiple transactions at prices ranging from $63.6700 to $63.7400. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, full information regarding the number of shares sold at each price.
Adjusted in connection with the spin-off of Covidien's pharmaceuticals business.
Options become exercisable in equal installments on each of the first, second, third and fourth anniversary of the grant date.